{"id":4308,"date":"2026-11-11T09:00:00","date_gmt":"2026-11-11T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4308"},"modified":"2026-11-14T12:48:27","modified_gmt":"2026-11-14T16:48:27","slug":"detalimogene-pivotal-cohort-durability-update","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4308","title":{"rendered":"Detalimogene Pivotal Cohort Durability Update"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_enGene_Detalimogene_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4319\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_enGene_Detalimogene_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_enGene_Detalimogene_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_enGene_Detalimogene_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_enGene_Detalimogene_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_enGene_Detalimogene_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>enGene<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Pivotal cohort data update (LEGEND)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Nonviral intravesical IL-12 gene therapy<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Detalimogene voraplasmid<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Local IL-12 expression in bladder urothelium<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>BCG-unresponsive non-muscle-invasive bladder cancer<\/p>\n<h4>Summary<\/h4>\n<p>Source-gap reconciliation: enGene\u2019s November 11 update of its single-arm pivotal LEGEND cohort reported 56% complete response at any time and a preliminary 43% Kaplan\u2013Meier estimate of response durability at 12 months in high-risk BCG-unresponsive non-muscle-invasive bladder cancer. The durability update is clinically material while cross-trial comparisons remain unreliable.<\/p>\n<p>Cohort 1 enrolled 125 patients with carcinoma in situ with or without papillary disease; 120 were efficacy-evaluable at the October 29 cutoff. The 12-month landmark complete-response rate was 24% among 110 assessed; median response duration was 10.1 months and median follow-up among responders 12.0 months. Nine patients had pending durability assessments. The company reported serious treatment-related adverse events in 2%. enGene says a pre-BLA FDA meeting aligned on the efficacy-evaluable population and plans to begin submission before year end and complete it in first-half 2027; these are prospective milestones, not regulatory acceptance.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>Detalimogene is a nonviral plasmid encoding interleukin-12, delivered intravesically with a carrier intended to transfect bladder urothelium. Local IL-12 expression aims to recruit antitumor immunity. <strong>Interpretation A:<\/strong> the maturing response and modest reported serious toxicity could support a bladder-preserving option; the within-cohort improvement from April supports that view.<\/p>\n<p><strong>Interpretation B:<\/strong> delayed assessments, changing denominators, informative censoring and absence of randomization may make apparent durability unstable. The product has no head-to-head comparison with approved intravesical options, and long-term cystectomy-free survival, progression and exposure data are needed. Ease of administration and potential community adoption are company claims, not demonstrated access outcomes. IL-12-related local or systemic inflammatory risk requires continued surveillance.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>BCG-unresponsive non-muscle-invasive bladder cancer can progress to muscle-invasive disease; radical cystectomy is a definitive but morbid option. Detalimogene voraplasmid is an investigational intravesical nonviral IL-12 gene therapy intended to stimulate local antitumor T-cell activity.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Signal: updated pivotal durability plus pre-submission regulatory interaction.<\/li>\n<li>Missing: independent full dataset, exact censoring, confirmed regulatory filing, long-term progression, cystectomy-free survival and comparative safety.<\/li>\n<li>Upgrade: accepted BLA, stable 12-month durability in complete follow-up and reproducible real-world outcomes.<\/li>\n<li>Downgrade or falsify: materially lower durability after remaining assessments or unanticipated toxicity.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The new data strengthen the rationale for regulatory review, but approval probability and relative clinical benefit cannot be quantified from this open-label report.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high for company-reported counts and estimates. Confidence in Interpretation: moderate to low because durability is preliminary and uncontrolled.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Source-gap reconciliation: enGene\u2019s November 11 update of its single-arm pivotal LEGEND cohort reported 56% complete response at any time and a preliminary 43% Kaplan\u2013Meier estimate of response durability at 12 months in high-risk BCG-unresponsive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4319,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[661,1495,1494],"class_list":["post-4308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-bladder-cancer","tag-detalimogene-voraplasmid","tag-engene"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4308"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4308\/revisions"}],"predecessor-version":[{"id":4333,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4308\/revisions\/4333"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4319"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}